Burkhart Erin 4

What Happened
Erin Burkhart, SVP, Controllership at Gilead Sciences (GILD), received equity awards on March 10, 2026 consisting of restricted stock units (RSUs). The filing shows two entries: 2,355 RSUs (reported as derivative, price N/A) and 5,455 RSUs at $0.00, for a total of 7,810 RSUs. These are awards (not open‑market purchases or sales) and represent contingent rights to company shares rather than immediately owned shares.

Key Details

• Transaction date: 2026-03-10; Form 4 filed: 2026-03-12 (appears timely within the two-business-day reporting window).
• Grants: 2,355 RSUs (derivative, price N/A) + 5,455 RSUs at $0.00 = 7,810 RSUs total.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes of note:
  • F1: Each RSU represents the contingent right to receive one share of Gilead common stock.
  • F2: RSUs vest over 4 years — 25% at year one, then 6.25% quarterly thereafter.
  • F3: Notes Gilead’s stock options also use a 4-year vesting schedule (no option exercise shown in this filing).
• Filing timeliness: filed two days after the transaction date; appears timely (no late-flag indicated).

Context
RSUs are compensation awards that convert into actual shares only as they vest and are typically subject to tax withholding. Such grants are routine executive compensation and do not necessarily indicate the insider’s view of near-term stock performance; purchases are generally viewed as stronger signals of personal bullishness.